Peptides for Libido and Sexual Health — The Complete Guide

Melanocortin MC3R/MC4R Agonism · Hypothalamic Dopaminergic Activation · Central Desire Signal

PT-141 is the only FDA-approved peptide for hypoactive sexual desire disorder and the most pharmacologically direct libido intervention available. It acts as an agonist at melanocortin MC3R and MC4R receptors in the hypothalamus, activating the dopaminergic and noradrenergic arousal pathways that generate sexual desire. This mechanism is fundamentally different from PDE5 inhibitors like sildenafil and tadalafil, which act peripherally on vascular smooth muscle without affecting the central desire state. PT-141 increases desire first — the arousal response that follows is the biological consequence of restored central drive. This distinction makes PT-141 effective across both sexes and across both desire-deficit and arousal-deficit presentations. At VitalRx, PT-141 is available as a subcutaneous injectable (2mg/mL, 5mL) and as a nasal spray (2.5mg/spray).

GnRH Pulse Restoration · LH/FSH Recovery · Endogenous Testosterone & Estrogen Production

Kisspeptin is the neuropeptide that sits directly upstream of GnRH release — the master regulator of GnRH pulse generation and the primary endogenous driver of the entire HPG axis. When kisspeptin signaling is suppressed — by chronic stress, caloric restriction, overtraining, aging, or hypothalamic dysfunction — GnRH pulse frequency falls, LH and FSH decline, and testosterone and estrogen production decreases. Exogenous Kisspeptin restores the upstream GnRH drive, stimulating LH and FSH secretion and restoring endogenous sex hormone production through the natural pituitary-gonadal pathway. Unlike direct testosterone replacement, Kisspeptin preserves testicular function, fertility, and the HPG feedback architecture. Kisspeptin also has direct central effects on sexual motivation circuits — Kisspeptin receptors are expressed in limbic system regions governing sexual behavior.

Bonding-Circuit Activation · Amygdala Anxiety Reduction · Physiological Arousal Amplification

Oxytocin — the posterior pituitary neuropeptide governing bonding, trust, and social connection — is also one of the most important modulators of sexual desire and arousal in the relational context. Central oxytocin receptor activation promotes approach motivation, trust, and emotional openness that are prerequisites for desire in intimate relationships. Oxytocin's role extends beyond psychology: it amplifies central arousal signaling by reducing amygdala-mediated threat and anxiety responses that suppress sexual desire in the presence of stress or performance pressure. It also directly facilitates physiological arousal — promoting genital blood flow, orgasm intensity, and physical intimacy sensations. At VitalRx, oxytocin is available as a nasal spray (100 IU/mL, 5mL) and as troches (50IU or 120IU, 30ct).

GABAergic Anxiolysis · HPA Axis Normalization · CRF Suppression · Serotonin Stabilization

Cortisol is the primary biological antagonist of reproductive drive. The HPA stress axis and the HPG reproductive axis are in direct neurobiological competition — CRF secreted under stress simultaneously activates cortisol production and suppresses GnRH pulsatility, directly reducing LH, testosterone, and estrogen. This is the specific mechanism by which psychological stress translates into hormonal suppression and libido loss. Selank — in the Semax/Selank combined nasal spray — provides GABAergic anxiolysis and serotonin system stabilization that directly reduces the HPA cortisol response driving reproductive axis suppression. It also addresses performance anxiety, rumination, and psychological arousal barriers. For patients where anxiety, stress, or psychological pressure is the dominant factor, Selank is frequently more impactful than direct arousal compounds.

Primary Libido Compound

• Acts centrally — increases sexual desire and drive before physiological arousal, not as a peripheral override
• Effective in both men and women — the only peptide with FDA approval for HSDD in women (as bremelanotide/Vyleesi)
• Activates hypothalamic dopaminergic arousal pathways — generates subjective desire rather than just physical response
• Does not require sexual stimulation to initiate effect — activates the central desire state directly
• Works regardless of hormonal status — relevant for postmenopausal women and men with low T
• As-needed or protocol dosing — flexibility for both on-demand and regular libido improvement use

• Same central MC3R/MC4R mechanism as injectable — desire-initiating, not just arousal-facilitating
• Non-injection delivery — preferred for patients who want as-needed use without subcutaneous administration
• Rapid intranasal CNS uptake — mucosal absorption bypasses first-pass metabolism for direct CNS delivery
• 2.5mg per spray — equivalent effective dose to injectable for most patients
• Convenient pre-encounter format — discreet, portable, no preparation required
• Effective in both men and women across all libido-deficit presentations

• Stimulates GnRH pulsatility directly — the most upstream available intervention on the HPG axis
• Drives LH and FSH secretion → restores endogenous testosterone and estrogen production
• Preserves testicular function and fertility — unlike direct testosterone replacement
• Addresses functional HPG axis suppression from chronic stress, overtraining, or hypothalamic dysfunction
• Direct limbic system effects on sexual motivation circuits — independent of its hormonal mechanism
• Most appropriate when hormonal libido deficit has a central (HPG suppression) rather than primary gonadal cause

• Activates central oxytocin receptors to promote emotional openness and trust — prerequisites for desire in relational context
• Reduces amygdala-mediated anxiety and threat responses that suppress arousal in the presence of performance pressure
• Amplifies physiological arousal — promotes genital blood flow and orgasm intensity
• Rapid intranasal CNS delivery — suitable for administration 20–30 minutes before sexual activity
• Most affordable libido compound in the VitalRx catalog — the appropriate starting point for contextual libido loss
• Effective in both men and women — the bonding and anxiety-reduction mechanisms are sex-independent

• Sublingual delivery — slower, more sustained oxytocin absorption than nasal spray
• Appropriate when prolonged intimacy support through an encounter is preferred over rapid onset
• 50IU moderate dose — suitable starting point for oxytocin-naive patients
• No injection required — fully non-invasive delivery
• Same central bonding and anxiety-reduction mechanism as nasal spray
• Combine with PT-141 injectable for the full dual-mechanism protocol

• 120IU — higher dose for patients where stronger or more sustained oxytocin effect is desired
• Sublingual sustained release — appropriate for longer encounters or extended intimacy-circuit support
• Same price as 50IU troche — cost advantage at higher dose per unit
• Effective for patients who found 50IU troches provided insufficient duration or intensity
• Combines with both PT-141 formats for the full arousal + bonding protocol

• Selank: reduces HPA axis cortisol output that directly suppresses GnRH, testosterone, and reproductive drive
• GABAergic anxiolysis eliminates performance anxiety that blocks arousal even when desire is present
• Serotonin system stabilization — relevant for patients whose libido loss has an SSRI-like pattern
• Removes the psychological and cortisol-driven inhibitor of arousal that PT-141 alone cannot overcome
• Rapid intranasal CNS delivery — administer 30–60 minutes before activity for the full anxiolytic effect
• Semax component provides concurrent cognitive and mood benefits

Patients with persistently reduced or absent sexual desire not explained by acute stress or relationship factors — where the central desire signal itself is the deficit.

Patients whose libido was previously normal and has declined in correlation with chronic stress, life events, anxiety, or relationship tension — where the HPA-HPG axis competition is the primary mechanism.

Patients with libido loss driven by hormonally confirmed low testosterone or estrogen — particularly those with secondary hypogonadism, overtraining syndrome, or hypothalamic amenorrhea.

Patients who have situational or contextual desire — present in some circumstances but absent in others — where emotional, relational, and anxiety-related barriers are the primary modifying factor.

First Use

Acute Arousal and Anxiety Effects

PT-141 effects are typically apparent from the first dose — patients report increased sexual desire, spontaneous arousal, and heightened physical sensitivity within 30–60 minutes. Common initial effects include mild flushing and, in some patients, transient nausea — both typically resolve within 1–2 hours. Oxytocin nasal spray's bonding-circuit and anxiety-reduction effects are generally felt within 20–30 minutes. Selank's anxiolytic effects are typically apparent within 30–60 minutes for patients with identifiable performance or contextual anxiety.

Weeks 2–6

HPG Axis Recovery and Protocol Accumulation

Kisspeptin's HPG axis effects accumulate through this window — LH pulsatility increases progressively, followed by testosterone or estrogen recovery over 3–6 weeks. Patients using Selank regularly report a gradual reduction in background anxiety and cortisol-driven arousal inhibition. Most patients report that their overall libido baseline — not just the acute compound effects — begins to improve by weeks 3–6.

Months 2–4+

Hormonal and Baseline Normalization

For patients with Kisspeptin-supported HPG axis restoration, testosterone and estrogen normalization consolidates alongside the continuing PT-141 and Oxytocin protocol. The most comprehensive libido improvement — across desire, arousal quality, hormonal baseline, and psychological barriers — typically develops as a compounding effect over months of consistent protocol adherence. Many patients maintain a maintenance protocol after achieving their baseline libido restoration.

PT-141 Injectable — 2mg/mL, 5mL

Central melanocortin arousal in men and women. Same mechanism as FDA-approved Vyleesi.

PT-141 Nasal Spray — 2.5mg/spray

Non-injection central arousal via intranasal delivery. Preferred for as-needed use.

Kisspeptin Injectable — 1mg/mL, 5mL

Upstream HPG axis GnRH stimulation. Restores endogenous testosterone and estrogen.

Oxytocin Nasal Spray — 100IU/mL, 5mL

Bonding-circuit activation, arousal amplification, and anxiety reduction.

Oxytocin Troche 50IU — 30ct

Sublingual oxytocin for sustained bonding and intimacy support.

Oxytocin Troche 120IU — 30ct

Higher-dose sublingual oxytocin for stronger or more sustained effect.

Semax / Selank Nasal Spray

Selank HPA normalization and GABAergic anxiolysis for stress-driven libido suppression.

Identify Your Primary Pattern

Is the core issue absent or markedly reduced desire — suggesting PT-141 as the primary compound? Stress or anxiety as a clear trigger — suggesting Selank first? Hormonal changes or confirmed low testosterone/estrogen — suggesting Kisspeptin for HPG axis restoration? Or contextual and relational barriers — suggesting Oxytocin as the starting point?

Complete Your Async Provider Consultation

Answer a brief health intake describing your libido history, how it has changed, what circumstances correlate with the change, any hormonal testing you have done, and relevant medications. If you have a recent hormone panel (testosterone, LH, FSH, estradiol), include it — it significantly improves protocol specificity.

Receive Your Order

Your prescription is filled by Optimal Balance Pharmacy and shipped via FedEx Standard Overnight. Syringes and alcohol swabs included with all injectable orders.

Layer the Protocol Over Time

Most libido protocols start with one or two acute-acting compounds — PT-141 and Oxytocin for immediate central arousal and intimacy effects — and add hormonal and stress-axis layers as the protocol matures. Full protocol effect is typically established by weeks 6–10.